Short Interest in NuCana plc (NASDAQ:NCNA) Drops By 66.9%

NuCana plc (NASDAQ:NCNA) saw a significant drop in short interest in February. As of February 15th, there was short interest totalling 17,700 shares, a drop of 66.9% from the January 31st total of 53,500 shares. Based on an average daily volume of 123,500 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.5% of the company’s stock are sold short.

Institutional Investors Weigh In On NuCana

A number of institutional investors have recently added to or reduced their stakes in NCNA. Virtu Financial LLC bought a new stake in NuCana during the fourth quarter valued at about $48,000. Two Sigma Securities LLC bought a new stake in NuCana during the fourth quarter valued at about $25,000. Schonfeld Strategic Advisors LLC bought a new stake in NuCana during the fourth quarter valued at about $54,000. Finally, Citadel Advisors LLC bought a new stake in NuCana during the fourth quarter valued at about $30,000. Institutional investors own 44.00% of the company’s stock.

NuCana Stock Performance

NCNA stock traded up $0.04 during trading on Friday, reaching $0.97. 25,621 shares of the company traded hands, compared to its average volume of 74,765. NuCana has a 12 month low of $0.85 and a 12 month high of $19.41. The business has a 50 day simple moving average of $1.09 and a 200 day simple moving average of $2.09. The company has a market capitalization of $2.56 million, a price-to-earnings ratio of -0.09 and a beta of 0.96.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.